Premium
Crossroads in GDNF therapy for Parkinson's disease
Author(s) -
Sherer Todd B.,
Fiske Brian K.,
Svendsen Clive N.,
Lang Anthony E.,
Langston J. William
Publication year - 2006
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.20861
Subject(s) - glial cell line derived neurotrophic factor , parkinson's disease , medicine , physical medicine and rehabilitation , neuroscience , psychology , disease , neurotrophic factors , receptor
The development of a neuroprotective or neuroregenerative therapy for Parkinson's disease (PD) would be a major therapeutic advance. Unfortunately, results from a recent controlled clinical study delivering the neurotrophic factor, glial‐derived neurotrophic factor (GDNF), directly into brain did not demonstrate efficacy and safety of such a treatment. A critical review of available data suggests that there are questions that need to be answered before the future of GDNF as a therapy for PD can be determined. © 2006 Movement Disorder Society